Change in transaminases in hepatitis C virus- and HIV-coinfected patients after highly active antiretroviral therapy: Differences between complete and partial virologic responders?

AIDS Research and Human Retroviruses

Volumn 16, Issue 11, 2000, Pages 1021-1023

  Gavazzi, G ^a   Bouchard, O ^a   Leclercq, P ^a   Morel Baccard, C ^a   Bosseray, A ^a   Dutertre, N ^a   Micoud, M ^a   Morand, P ^a  

^a HÔPITAL MICHALLON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PRIORITY JOURNAL; T LYMPHOCYTE; VIREMIA; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPARTATE AMINOTRANSFERASES; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; MALE; RNA, VIRAL; TRANSAMINASES; VIRAL LOAD; VIREMIA;

EID: 2342424891     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220050075264     Document Type: Article

References (14)

1. 1. Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, and Stolt-Keller F: High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995;9:1131-1136.
2. 2. Rockstroh JK, Spengler U, Sudhop T, et al.: Immunosuppression may lead to progression of hepatitis C virus associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996;91:2563-2568.
3. 3. Pol S, Fontaine H, Carnot F, Zylberberg H, Berthelot P, Bréchot C, and Nalpas B: Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: A comparison between immunocompetent and immunocompromised patients. J Hepatol 1998;29:12-19.
4. 4. Garcia-Samaniego J, Soriano V, Castilla, J, et al.: Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. Am J Gastroenterol 1997;92:1130-1134.
5. 5. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-733.
6. 6. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, and Autran B: Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-1686.
7. 7. Gilquin J, Piketty C, Thomas V, Gonzales-Canali G, Belec L, and Kazatchkine MD: Acute cytomegalovirus infection in AIDS patients with CD4 counts above 100 × 10(6) cells/1 following combination antiretroviral therapy including protease inhibitors. AIDS 1997;11:1659-1660.
8. 8. Nussenblat RB and Lane HC: Human immunodeficiency virus disease: Changing patterns of intraocular inflammation. Am J Ophthalmol 1998;125:374-382.
9. 9. John M, Flexman J, and French MAH: Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with protease inhibitors: An immune restoration disease? AIDS 1998;12:2289-2293.
10. 10. Rutschmann OT, Negro F, Anwar D, Hirschel B, Hadengue A, and Perrin L: Impact of HIV protease inhibitor on HCV viremia. J Infect Dis 1998;177:783-785.
11. 11. Zylberberg H, Chaix ML, Rabian C, et al.: Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects. Clin Infect Dis 1998; 26:1104-1106.
12. 12. Rockstroh JK, Theisen A, Kaiser R, Sauerbruch T, and Spengler U: Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV-coinfected haemophiliacs. AIDS 1998;12:829-830.
13. 13. Rodriguez-Rosado R, Garcia-Samaniego J, Soriano V, Munoz F, and Gonzalez-Lahoz J: Hepatotoxicity after introduction of highly active antiretroviral therapy (HAART). In: Program and abstracts of the 12th World AIDS Conference, Geneva, 1998. [Abstract 12288]
14. 14. Nelson DR, Marousis CG, Davis GL, et al.: The role of hepatitis C virus-specific cytotoxic lymphocytes in chronic hepatitis C. J Immunol 1997;158:1473-1481.